Related Experiment Video

Updated: Oct 15, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation

A Keogh1, P Macdonald, A Kaan

  • 1Heart Transplant Unit and Victor Chang Research Unit, St. Vincent's Hospital, Sydney, Australia. akeogh@stvincents.com.au

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|June 27, 2000
PubMed

Insights

Pravastatin demonstrated superior safety and a trend towards better survival compared to simvastatin in heart transplant recipients. Pravastatin showed fewer muscle-related side effects and immunosuppression-related deaths, making it the preferred statin post-transplant.

Area of Science:

  • Cardiology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Statins are crucial for managing lipid profiles in cardiac transplant recipients.
  • Prior studies suggest benefits of pravastatin and simvastatin in reducing mortality and intimal thickening.
  • Understanding comparative safety and efficacy is vital for post-transplant care.

Purpose of the Study:

  • To compare the safety and efficacy of pravastatin versus simvastatin in cardiac transplant recipients.
  • To evaluate lipid levels, rejection rates, and survival outcomes between the two statin groups.
  • To identify the optimal statin for post-cardiac transplantation management.

Main Methods:

  • An observational study involving 87 cardiac transplant recipients.
  • Patients received open-label pravastatin 40 mg or simvastatin 20 mg daily.
  • Comparison of lipid profiles, safety events (rhabdomyolysis, myositis), and post-transplant outcomes over 12 months.

Main Results:

  • No significant differences in lipid profiles or rejection rates were observed between pravastatin and simvastatin groups.
  • Rhabdomyolysis and myositis occurred significantly more in the simvastatin group (13.3%) than the pravastatin group (p=0.032).
  • Pravastatin showed a trend towards superior 12-month survival (97.6% vs 83.7%) with fewer immunosuppression-related deaths.

Conclusions:

  • Pravastatin and simvastatin yield comparable lipid-lowering effects in cardiac transplant recipients.
  • Pravastatin offers a superior safety profile, notably lacking the muscle-related adverse events seen with simvastatin.
  • Pravastatin is recommended as the statin of choice post-heart transplantation due to safety and pharmacokinetic advantages.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...